Stay updated with breaking news from Beckley Psytech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub
(Bloomberg) -- Atai Life Sciences NV agreed to acquire a stake in smaller rival Beckley Psytech to expand its portfolio of drug candidates for the treatment of mental health conditions. Most Read from BloombergConfidential Jeffrey Epstein Documents Unsealed by New York CourtFed Sees Rates Staying High for Some Time With Cuts Eyed in 2024Saving the Panama Canal Will Take Years and Cost Billions, If It’s Even PossibleTech Stocks Log Four-Day Losing Streak, Bonds Rise: Markets WrapIran Blasts That
Biopharma and resources-pooling company Atai Life Sciences (NASDAQ: ATAI) has invested a total of $50 million in Beckley Psytech Ltd., a U.K.-based clinical-stage biotech advancing short-duration psychedelics for neuropsychiatric conditions.
Strategic investment in Beckley Psytech reinforces atai's position as the biopharmaceutical company with the largest and most diverse portfolio of…